trending Market Intelligence /marketintelligence/en/news-insights/trending/U8X4vGUoYo1uOziV6DuZ4Q2 content esgSubNav
In This List

Seres Therapeutics ulcerative colitis drug nabs US FDA orphan drug designation

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Seres Therapeutics ulcerative colitis drug nabs US FDA orphan drug designation

Seres Therapeutics Inc. said the U.S. Food and Drug Administration granted orphan drug designation to its SER-287 microbiome therapeutic candidate for treating pediatric patients with ulcerative colitis.

The designation follows a review of data from the phase 1b study evaluating SER-287 for ulcerative colitis treatment. The company expects results from the trial in early 2018.

Ulcerative colitis is a serious chronic condition affecting about 700,000 people in the U.S. The disease results in inflammation of the colon and rectum and may lead to colon removal.